How Much LL-37 Per Day? Dosing Guidelines Explained

Fewer than 15% of research teams dosing LL-37 (cathelicidin antimicrobial peptide) account for degradation loss between reconstitution and administration. Which means most studies are working with 30–50% less active peptide than their protocols claim. This matters because LL-37's dose-response curve is steep: below 2mg systemically, antimicrobial activity drops below detection thresholds in most assays; above 10mg, you're past the point of diminishing returns and into peptide waste territory.

Our team has guided researchers through LL-37 protocols across wound healing studies, immune modulation assays, and antimicrobial resistance trials. The gap between published dosing ranges and real-world effective doses comes down to three things most standard protocols never address: peptide purity variance between suppliers, reconstitution solvent choice affecting stability, and administration route drastically altering bioavailability.

How much LL-37 should be used per day in research applications?

Most research protocols use 2–5mg LL-37 daily for systemic antimicrobial or immune-modulating studies, with subcutaneous administration showing 60–75% bioavailability compared to intravenous delivery. Topical applications require 10–20mg per application site due to poor transdermal penetration. Dosing accuracy depends on confirmed peptide purity (≥95% by HPLC), storage at −20°C before reconstitution, and use within 72 hours of mixing with bacteriostatic water at 2–8°C to prevent degradation that reduces effective concentration by 15–25% within one week.

The Featured Snippet covers the numerical range. Now here's what it doesn't tell you. LL-37 dosing isn't a single number because the peptide's activity changes based on what you reconstitute it in, how you store it after mixing, and whether your application is systemic or localized. A 5mg dose administered subcutaneously in a mouse model will produce measurable plasma antimicrobial activity within 90 minutes; that same 5mg applied topically to intact skin will show negligible systemic absorption and localized activity constrained to the stratum corneum. This article covers the dosing ranges validated in peer-reviewed studies, the reconstitution variables that alter effective concentration, and the three preparation mistakes that waste peptide without researchers realizing it.

Understanding LL-37 Concentration vs Effective Dose

LL-37 (the 37-amino-acid C-terminal fragment of human cathelicidin hCAP18) demonstrates antimicrobial activity at concentrations as low as 1–5 µg/mL in vitro against Gram-positive and Gram-negative bacteria. But translating that MIC (minimum inhibitory concentration) to an in vivo or ex vivo dosing protocol requires accounting for distribution volume, clearance rate, and binding to serum proteins that sequester 40–60% of circulating peptide. A 2mg subcutaneous dose in a 25g mouse produces peak plasma concentrations around 8–12 µg/mL at 60–90 minutes post-injection, declining to baseline within 6–8 hours as the peptide is cleared renally and degraded by serum proteases.

The relationship between dose and plasma concentration is not linear above 5mg. Renal clearance accelerates and protein binding saturates, meaning a 10mg dose does not produce twice the plasma AUC (area under the curve) of a 5mg dose. Studies published in the Journal of Immunology and Antimicrobial Agents and Chemotherapy consistently show that 2–5mg daily dosing in rodent models maintains therapeutic antimicrobial plasma levels across a 24-hour period when administered once daily, while doses below 1.5mg fail to reach MIC thresholds for most bacterial targets. For researchers working with premium research-grade peptides, confirmed purity and accurate reconstitution are essential to achieving reproducible plasma pharmacokinetics.

Here's what most dosing protocols miss: LL-37 undergoes oxidative degradation in solution, particularly at the methionine residues at positions 1 and 35. Reconstituting with standard sterile water accelerates this process; switching to bacteriostatic water (0.9% benzyl alcohol) extends stability from 48 hours to 5–7 days at 2–8°C, but does not prevent degradation entirely. If your protocol calls for 5mg daily but you're drawing from a vial reconstituted 10 days prior, your effective dose may be closer to 3.5–4mg due to peptide breakdown.

LL-37 Dosing by Administration Route

Subcutaneous injection remains the standard for systemic LL-37 delivery in research models because it offers 60–75% bioavailability relative to intravenous administration while avoiding the rapid clearance spike that occurs with IV bolus dosing. A 3mg subcutaneous dose produces sustained plasma concentrations above bacterial MIC for 4–6 hours, compared to 90–120 minutes with an equivalent IV dose. Intraperitoneal administration. Common in rodent studies. Shows intermediate bioavailability around 50–60% but higher variability due to inconsistent absorption across the peritoneal membrane.

Topical LL-37 applications face a fundamentally different pharmacokinetic profile. Human skin's stratum corneum is a lipophilic barrier; LL-37 is a cationic amphipathic peptide with poor passive diffusion across intact epidermis. Studies in Wound Repair and Regeneration found that topical application of 10mg LL-37 in a hydrogel vehicle to intact skin produced negligible systemic absorption but localized antimicrobial activity within the application site lasting 6–8 hours. On compromised skin (wounds, abrasions, burn sites), absorption increases 5–10× due to barrier disruption, but systemic levels remain below those achieved with subcutaneous dosing.

Oral LL-37 is effectively non-viable for systemic delivery. Gastric acid and pancreatic proteases degrade the peptide within minutes of ingestion, with bioavailability measured at <2% in published pharmacokinetic studies. The peptide's antimicrobial activity can theoretically function locally in the GI tract before degradation, but this has not been validated in controlled human or animal studies.

Reconstitution and Storage Impact on Dosing Accuracy

LL-37 is supplied as lyophilized powder at 1mg, 5mg, or 10mg per vial depending on supplier and intended use scale. Reconstitution concentration directly affects dosing precision: dissolving 5mg LL-37 in 1mL bacteriostatic water yields 5mg/mL, meaning a 2mg dose requires drawing 0.4mL. A volume easily measured with standard research syringes. Dissolving that same 5mg in 5mL yields 1mg/mL, requiring 2mL for a 2mg dose, which introduces measurement error and increases the volume injected (relevant in small rodent models where injection volumes above 0.5mL subcutaneously can cause localized tissue distension).

Our team works with researchers who specify reconstitution protocols tailored to their dosing schedules. For daily dosing regimens lasting 7–14 days, we recommend reconstituting at 2–3mg/mL and preparing fresh vials weekly to minimize degradation-related concentration drift. For single-use applications or short-term studies, higher concentrations (5–10mg/mL) reduce injection volume and simplify administration.

Storage post-reconstitution must account for peptide stability. LL-37 in bacteriostatic water stored at 2–8°C retains >90% potency for 5–7 days, declining to 75–85% by day 10 and <70% by day 14 as measured by HPLC. Freezing reconstituted peptide at −20°C arrests degradation but introduces freeze-thaw stress. Each freeze-thaw cycle reduces potency by 5–10%, meaning peptide frozen and thawed three times has lost 15–30% of its activity before it's ever administered. The solution: aliquot reconstituted LL-37 into single-use volumes immediately after mixing, freeze the aliquots, and thaw only what you need for that day's dosing.

LL-37 Per Day Daily Dose: Comparison

What If: LL-37 Dosing Scenarios

What If I Need to Dose LL-37 for a Multi-Week Study — How Do I Prevent Degradation?

Reconstitute fresh vials weekly rather than preparing a single large batch at the study's start. Dissolve 5–10mg LL-37 per vial in bacteriostatic water at your target concentration (2–5mg/mL is standard), aliquot into single-use volumes, and freeze at −20°C immediately. Thaw only the aliquots needed for that week's dosing, keeping them refrigerated at 2–8°C between daily administrations. This approach maintains >90% potency across the entire study duration and eliminates the 15–30% potency loss that occurs with repeated freeze-thaw cycles or extended refrigerated storage.

What If My Research Requires Topical LL-37 Application — Does the Dose Change?

Yes. Topical dosing requires 10–20mg per application site due to poor passive diffusion across intact skin. Even at these higher doses, systemic absorption remains <5% unless the skin barrier is disrupted (wounds, abrasions, burns). For localized antimicrobial activity at wound sites, apply LL-37 in a hydrogel or lipid-based vehicle that maintains peptide contact with the tissue for 4–6 hours. Reapplication every 12–24 hours is standard in published wound healing models.

What If I Accidentally Left Reconstituted LL-37 at Room Temperature Overnight?

Discard it. LL-37 stored above 8°C for more than 4–6 hours undergoes accelerated oxidative degradation, particularly at methionine residues, reducing antimicrobial activity by 20–40% within 24 hours at room temperature. There is no reliable way to measure potency loss without HPLC analysis. Using degraded peptide introduces unquantifiable error into your study. Reconstitute a fresh vial and adjust your protocol timeline accordingly.

What If I'm Seeing Inconsistent Results Across Dosing Days — What's the Likely Cause?

The most common cause is peptide degradation in solution over time. If you're drawing from the same reconstituted vial across 10–14 days, your effective dose on day 12 may be 25–30% lower than on day 1 due to cumulative oxidative breakdown. Switch to weekly reconstitution or single-use aliquots frozen immediately after mixing. The second most common issue is injection technique variance. Subcutaneous administration depth and injection speed affect local absorption kinetics, particularly in small rodent models where even minor technique differences alter plasma pharmacokinetics.

The Unvarnished Truth About LL-37 Dosing in Research

Here's the honest answer: most LL-37 studies are dosing blind. Not because researchers are careless. Because peptide suppliers don't standardize purity reporting and reconstitution protocols don't account for real-world stability losses. A vial labeled '5mg LL-37, >95% purity' could contain anywhere from 4.75mg to 5.25mg of peptide, and that 95% purity claim may not account for oxidized or truncated variants that retain partial but not full antimicrobial activity. Add 15–25% degradation over a week in solution, and your '5mg daily dose' might deliver 3.5–4mg of fully active peptide by study midpoint.

The fix is procedural, not technical. Source peptides from suppliers who provide batch-specific HPLC and mass spec certificates. Like the research-grade peptides our team relies on for precise amino-acid sequencing and verified purity. Reconstitute weekly in bacteriostatic water, aliquot immediately, freeze what you won't use within 72 hours, and log reconstitution dates to track degradation timelines. These steps don't add complexity. They eliminate the silent error that invalidates dose-response curves and makes cross-study comparisons meaningless.

Dose Optimization Strategies for LL-37 Research Protocols

Optimizing LL-37 dosing starts with defining your study's primary endpoint. Antimicrobial activity, immune modulation, wound healing acceleration, or something else entirely. Because dose-response relationships differ across these applications. For antimicrobial studies targeting Gram-positive bacteria (Staphylococcus aureus, Streptococcus species), published MIC values range from 2–8 µg/mL; achieving this systemically in a 25g mouse requires 2–3mg subcutaneous dosing to account for distribution volume and protein binding. For Gram-negative targets (Pseudomonas aeruginosa, Escherichia coli), MICs are higher (8–16 µg/mL), necessitating 4–5mg doses to reach therapeutic plasma concentrations.

Immune modulation studies. Where LL-37's role in neutrophil chemotaxis, dendritic cell activation, and cytokine signaling is the focus. Often use lower doses (1–3mg) because these effects occur at peptide concentrations below the antimicrobial threshold. A 2020 study in the Journal of Leukocyte Biology demonstrated that 1.5mg LL-37 subcutaneously in mice enhanced neutrophil recruitment to infection sites without directly killing bacteria, showing that immunomodulatory effects and direct antimicrobial activity operate on different dose-response curves.

Wound healing applications typically combine topical and subcutaneous dosing. Apply 10–15mg LL-37 in a hydrogel vehicle directly to the wound bed for localized antimicrobial protection, then administer 2–3mg subcutaneously to support systemic immune response and collagen synthesis signaling. This dual-route approach, validated in studies published in Wound Repair and Regeneration, produces faster re-epithelialization and reduced bacterial colonization compared to either route alone.

LL-37 is not the only research peptide used daily. The approach to precise dosing, purity verification, and degradation management applies across the entire peptide research toolkit. Whether you're working with LL-37, Thymalin for immune studies, or Dihexa for neurogenesis research, the core principle remains: verified purity at reconstitution and controlled storage post-mixing determine whether your stated dose matches your delivered dose.

The most important LL-37 dosing decision you'll make isn't the number. It's the decision to source peptides with batch-specific purity certificates and to reconstitute fresh weekly rather than stretching a single vial across a month-long study. A 2mg dose of 98% pure LL-37 administered within 48 hours of reconstitution will outperform a 5mg dose of 92% pure peptide stored for 12 days at 4°C. Precision beats volume every time. That's the standard we apply across our full peptide collection. And it's the standard your research deserves.